Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

Lymphoma

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Eur J Cancer

Fabbri N, Casadei B, Chiappella A, Stella F, Donzelli L, Galli E, Riva M, Martino M, Barbui AM, Musso M, Farina M, Angelillo P, Cutini I, Santoro A, Cavallo F, Rivela P, Castellino A, Krampera M, Petruzzellis G, Grillo G, Argnani L, Bonifazi F, Corradini P, Zinzani PL

doi: 10.1016/j.ejca.2026.116879

Lymphoma

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leuk Lymphoma

Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL

doi: 10.1080/10428194.2025.2525982

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Lymphoma

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Leuk Lymphoma

Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM

doi: 10.1080/10428194.2025.2604300

Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Am J Hematol

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF

doi: 10.1002/ajh.70033

Lymphoma

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Blood Cancer J

Perrone S, Molica M, Giannarelli D, Pacitto G, Ferrero S

doi: 10.1038/s41408-026-01552-5

Leukemia

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet

Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG

doi: 10.1016/S0140-6736(26)01204-3

Leukemia

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

Br J Haematol

Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L

doi: 10.1111/bjh.70334

Lymphoma

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

Blood Cancer J

Shi W, Xu-Monette ZY, Jia Y, Tzankov A, Go H, Li L, Ponzoni M, Wang Y, Zhai Q, Perry AM, Wang S, Wang X, Chiu A, Xu ML, Visco C, Dybkaer K, Withers H, Long M, Yuan AF, Miao Y, Macias E, Wu D, Shuai W, Wang B, Li J, Bhagat G, Zu Y, Pan Z, Choi W, Montes-Moreno S, Chen W, Krieken JHV, Møller MB, Yu X, Parsons BM, Zhang S, Hsi ED, Sohani AR, Abramson JS, Ferreri AJM, Xu B, Li Y, Young KH

doi: 10.1038/s41408-025-01323-8

Related content

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma